Inactive Instrument

Compugen Ltd. Share Price Deutsche Boerse AG

Equities

CW9

IL0010852080

Biotechnology & Medical Research

Real-time Estimate Tradegate 07:56:50 17/07/2024 pm IST 5-day change 1st Jan Change
1.705 EUR -66.24% Intraday chart for Compugen Ltd. -9.82% 0.00%

Financials

Sales 2024 * 37.04M 33.87M 3.09B Sales 2025 * 41.12M 37.6M 3.43B Capitalization 167M 153M 13.98B
Net income 2024 * -4M -3.66M -334M Net income 2025 * -1M -914K -83.51M EV / Sales 2024 * 4.52 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 4.07 x
P/E ratio 2024 *
-37.4 x
P/E ratio 2025 *
374 x
Employees 68
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.62%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Compugen Ltd.

Managers TitleAgeSince
Chief Executive Officer 57 01/02/01
Director of Finance/CFO 61 01/22/01
Chief Tech/Sci/R&D Officer - 01/15/01
Members of the board TitleAgeSince
Chairman 66 02/17/02
Director/Board Member 68 11/18/11
Director/Board Member 57 11/18/11
More insiders
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
More about the company